This temporal advantage holds substantial clinical importance, as early initiation of neuroprotective interventions such as dopamine agonists and monoamine oxidase-B inhibitors during the initial stages of neurodegenerative diseases has been shown to be significantly more effective than delayed treatment [46]. Here, MAOB is linked to neurodegenerative disease.